AstraZeneca Product Showcase: Tissue Stewardship in the Age of Comprehensive Biomarker Testing in NSCLC
Thursday, September 12 | 12:45 pm - 2:15 pm (Lunch provided) | West Building, 211 A-B
This Molecular Pathology program will explore optimal practices for tumor tissue sample collection and tissue handling in NSCLC, reinforce the importance of tumor tissue sample quantity and quality for comprehensive biomarker testing and clinical decision making in patients with NSCLC, review potential pre-analytic roadblocks to quality biomarker testing and discuss strategies for avoiding these roadblocks.
Non-Accredited - funded by AstraZeneca
Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer: Why, Who, and How
Thursday, September 12 | 1:00 pm - 2:00 pm (Lunch provided) | West Building, 101 A-B
This symposium provides the perfect opportunity for learners to gain insights from both medical oncology and pathology experts on the evolving understanding of biomarkers predictive of response to ICIs and development of immune-related toxicities. Topics include:
- • The Why and Who: Overview of Immune Checkpoint Blockade in Lung Cancer
- • The How: Current Predictors of Response to Immune Checkpoint Inhibitors
- • The Future: Development of New Predictive Biomarkers for Cancer Immunotherapy
CC/MOC/CMP Accredited - funded by AstraZeneca
Aptima Mycoplasma Genitalium Evaluation Study
Friday, September 13 | 6:45 am - 7:45 am (Breakfast provided) | West Building, 211 A-B
This presentation will provide an overview of Mycoplasma Genitalium, a highly prevalent yet overlooked sexually-transmitted pathogen, current diagnostic challenges, and prevalence. The session will provide a thorough review of the clinical validation study for Aptima Mycoplasma Genitalium Assay, the first FDA-cleared assay for the qualitative detection of this pathogen.
Non-Accredited – funded by Hologic, Inc.
Pathology Insights on Innovation in AML: The Rapid Emergence of Precision Diagnostics & Novel Therapy Across the Spectrum of Care
Friday, September 13 | 11:30 am - 12:30 pm (Lunch provided) | West Building, 101 A-B
This unique ‘MasterClass and Case Forum’ event will expose learners to the science that supports a modern approach to diagnosing AML (and its many subtypes) and optimizing the selection of subsequent treatment. Attendees will gain a key understanding of clinically relevant implications of recent evidence on novel therapeutics in AML, including where such evidence intersects with treatment decisions guided by molecular/pathology testing results. Content areas include Molecular Pathology, Education Best Practices for Pathologists and Laboratory Professionals, and Hematopathology.
CC/MOC/CMP Accredited – Funded by Jazz